The Motley Fool
28 Sept 2025, 12:30 UTC · 51w ago
Verdict
Headline takes no side. We score CRNX +0.60 across five claims — strongly bullish.
+0.60strongly bullish
More positive than 76% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
The FDA has approved Crinetics Pharmaceuticals' drug Palsonify as the first once-daily oral treatment for acromegaly.
So whatApproval transforms the company from clinical-stage to commercial-stage, fundamentally changing its valuation model and revenue potential.
More positive than 99% of claims this week
Palsonify is priced at $290,000 annually, though net revenue per patient is estimated at $175,000 to $200,000 after discounts.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 79% of claims this week
Wall Street peak sales estimates for the drug vary widely between $600 million and $1.5 billion.
More positive than 66% of claims this week
Management expects a gradual revenue ramp rather than immediate growth due to the time required for formulary placement and insurance negotiations.
More negative than 69% of claims this week
Potential for future growth exists through international expansion in Europe and Japan and a possible label extension for carcinoid syndrome.
More positive than 53% of claims this week
Which stocks this story touches
More positive than 76% of ticker scores this week
FDA approval of Palsonify transforms the company into a commercial powerhouse and caused a 28% stock surge, despite valuation concerns.
Near neutral — 92% of ticker scores this week are stronger
Goldman Sachs is mentioned as a source of a cautious valuation estimate for another company.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
6h ago
+85.0%
Price agrees with the score
$84.95 vs $45.91 close before publication (Sep 26) · not market-adjusted
CRNX chart →
